Listed by the USPTO as GROSS, CHRISTOPHER M
Tech Center 1600 • Art Units: 1612 1636 1639 1653 1675 1678 1684
This examiner grants 64% of resolved cases
Christopher M. Gross is a USPTO patent examiner in tech center 1600 and art unit 1612. The profile covers 668 resolved cases, with an allowance rate of 63.5% and a median of 1543 days to allowance. The interview lift is 40.2%, indicating a substantial measured association between interviews and allowance outcomes. The 1543-day median makes timing a central consideration for applicants developing prosecution, continuation, and market-entry plans.
The leading companies are Crystalsfirst GmbH, Trustees of Boston University, and Massachusetts Institute of Technology. The leading firms are MILLEN, WHITE, ZELANO & BRANIGAN, P.C., Carroll, Hoette & Butscher, LLC, and Casimir Jones, S.C. The docket reflects advanced materials and university research, with firms that handle technical and institutional applicants.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18408191 | SYSTEM FOR THE DIRECTED EVOLUTION OF BIOMOLECULES IN MULTI-BODY COMPLEXES | Non-Final OA | Massachusetts Institute of Technology |
| 18189056 | COMBINATORIAL PLATFORM FOR HIGH-THROUGHPUT POLYNUCLEOTIDE-ENCODED CATALYST DISCOVERY | Final Rejection | WISCONSIN ALUMNI RESEARCH FOUNDATION |
| 18051711 | METHOD TO QUANTIFY AFFINITY AND SELECTIVITY OF SMALL MOLECULES FOR PROTEINS IN LIVING CELLS | Non-Final OA | Ohio State Innovation Foundation |
| 18291773 | Methods and Compositions for Producing Cell-Source Identifiable Collections of Nucleic Acids | Non-Final OA | Takara Bio USA, Inc. |
| 18702311 | PRE-LIBRARY TARGET ENRICHMENT FOR NUCLEIC ACID SEQUENCING | Non-Final OA | University of Utah Research Foundation |
| 18230872 | TESTING COLON CANCER DRUGS FOR IMMUNOMODULATORY EFFECTS | Non-Final OA | BROWN UNIVERSITY |
| 17182044 | GENE EXPRESSION-BASED BIOMARKER FOR THE DETECTION AND MONITORING OF BRONCHIAL PREMALIGNANT LESIONS | Non-Final OA | Trustees of Boston University |
| 18697961 | METABOLIC ENGINEERING OF ACTINOMYCETES BY SINGLE CELL MUTANT SELECTION | Non-Final OA | Turun yliopisto |
| 18580463 | SCREENING CODON-OPTIMIZED NUCLEOTIDE SEQUENCES | Non-Final OA | TRANSLATE BIO, INC. |
| 17807954 | EXPRESS HUMANIZATION OF ANTIBODIES | Final Rejection | BioAtla, Inc. |
| 18579196 | TEMPORAL PROPERTY PREDICTOR | Non-Final OA | SHIFT BIOSCIENCE LTD. |
| 18487926 | MULTIPLE TAGGING OF INDIVIDUAL LONG DNA FRAGMENTS | Non-Final OA | Complete Genomics, Inc. |
| 17297944 | METHOD FOR PREDICTING THE RESPONSE TO CANCER IMMUNOTHERAPY IN CANCER PATIENTS | Final Rejection | Charité - Universitätsmedizin Berlin |
| 18353065 | BINDING ASSAYS USING PHAGE DISPLAY TECHNOLOGY AND KITS THEREOF | Final Rejection | Eurofins DiscoverX Corporation |
| 17370819 | METHODS AND COMPOSITIONS FOR THE DIAGNOSIS OF SEPSIS USING GAMMA PEPTIDE NUCLEIC ACIDS | Final Rejection | HELIXBIND, INC. |
| 18333339 | METHODS TO SELECT ANTIBODIES SPECIFIC TO COMPLEX MEMBRANE ANTIGENS | Non-Final OA | VACCINEX, INC. |
| 18025100 | ARRAY, SOAKING SOLUTIONS AND METHOD OF SELECTING SOAKING CONDITIONS FOR SMALL MOLECULES IN BIOLOGICAL MACROMOLECULAR CRYSTALS | Final Rejection | CRYSTALSFIRST GMBH |
| 18025103 | ARRAY, SOAKING SOLUTIONS AND METHOD OF SELECTING SOAKING CONDITIONS FOR SMALL MOLECULES IN BIOLOGICAL MACROMOLECULAR CRYSTALS | Final Rejection | CRYSTALSFIRST GMBH |
| 18025107 | ARRAY, SOAKING SOLUTIONS AND METHOD OF SELECTING SOAKING CONDITIONS FOR SMALL MOLECULES IN BIOLOGICAL MACROMOLECULAR CRYSTALS | Final Rejection | CRYSTALSFIRST GMBH |
| 18023909 | MAMMALIAN CELLS AND METHODS FOR ENGINEERING THE SAME | Final Rejection | 64-X, Inc. |
| 18008766 | SUBSTRATE FOR IMMOBILIZING SUBSTANCE, AND USE THEREOF | Final Rejection | R-NANOBIO CO. LTD. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy63.5% of resolved applications examined by Christopher M Gross were allowed (668 resolved cases), compared with 40.7% across Art Unit 1612 over the last five years.
This examiner's interview lift is +40.2 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Christopher M Gross took 1,543 days on average from filing to allowance.
Christopher M Gross examines applications in Art Unit 1612 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
